比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺方案在艾滋病定义疾病患者中的真实世界有效性与安全性:CoRIS队列ACTUAS II研究
该研究基于CoRIS队列,比较比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(BIC/FTC/TAF)与其他一线方案在90例和94例以艾滋病定义疾病起始抗逆转录病毒治疗的初治成人中的有效性与耐受性。第24周时BIC/FTC/TAF组病毒抑制比例更高(75.6% vs 56.5%;aOR 2.78),免疫恢复比例更低(47.7% vs 61.9%;aOR 0.49),但差异至第48周消失;BIC/FTC/TAF组治疗中断比例显著更低(第24周4.4% vs 20.2%;第48周10% vs 36.2%)。作者认为BIC/FTC/TAF是艾滋病患者起始抗逆转录病毒治疗的有效且耐受良好的选择。
要点
- 第24周BIC/FTC/TAF组病毒抑制率75.6% vs 其他方案组56.5%,aOR 2.78(95%CI 1.28-6.25)。
- 第24周BIC/FTC/TAF组免疫恢复率47.7% vs 其他方案组61.9%,aOR 0.49(95%CI 0.25-0.99)。
- BIC/FTC/TAF组治疗中断比例显著低于其他方案组(第24周4.4% vs 20.2%;第48周10% vs 36.2%)。
核心结论
- 作者认为,基于本研究结果,BIC/FTC/TAF是艾滋病患者起始抗逆转录病毒治疗的有效且耐受良好的选择。
研究设计与样本
- 研究为CoRIS队列研究,纳入以艾滋病定义疾病起始抗逆转录病毒治疗的初治成人,比较BIC/FTC/TAF与其他一线方案。
- 共分析90例起始BIC/FTC/TAF者和94例起始其他方案者,基线特征相似。
- 采用逻辑回归模型估计优势比(OR),评估第24周和第48周的病毒抑制(HIV RNA<50 copies/mL)和免疫恢复(CD4计数>200 cells/μL)。
主要发现
- 第24周,BIC/FTC/TAF组病毒抑制比例高于其他方案组(75.6% vs 56.5%;aOR 2.78 [95%CI 1.28-6.25])。
- 第24周,BIC/FTC/TAF组免疫恢复比例低于其他方案组(47.7% vs 61.9%;aOR 0.49 [95%CI 0.25-0.99])。
- 上述差异至第48周消失。
- BIC/FTC/TAF组治疗中断比例显著低于其他方案组(第24周4.4% vs 20.2%;第48周10% vs 36.2%)。
- 第48周,治疗中断的主要原因包括不良事件(3.3% vs 8.5%)、预防毒性(1.1% vs 8.5%)、简化抗逆转录病毒治疗(0% vs 10.6%)和治疗失败(2.2% vs 4.3%)。
关键数值与推荐
- 病毒抑制定义为HIV RNA<50 copies/mL。
- 免疫恢复定义为CD4计数>200 cells/μL。
- 第24周病毒抑制的aOR为2.78(95%CI 1.28-6.25),免疫恢复的aOR为0.49(95%CI 0.25-0.99)。
临床怎么用
- 作者认为,BIC/FTC/TAF是艾滋病患者起始抗逆转录病毒治疗的有效且耐受良好的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The comparative effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) has not been sufficiently evaluated in people with AIDS who initiate therapy. METHODS: The aim of the current study was to compare the effectiveness and tolerability of BIC/FTC/TAF with other first-line antiretroviral therapy (ART) regimens in treatment-naive adults from the CoRIS cohort who initiated ART with AIDS. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS), defined as human immunodeficiency virus RNA <50 copies/mL, and immunological recovery (IR), defined as CD4 count >200 cells/μL. Time to VS and the proportion of treatment discontinuations were also evaluated and compared, with all analyses conducted at weeks 24 and 48 after initiation of ART. RESULTS: We analyzed 90 individuals initiating ART with BIC/FTC/TAF and 94 with other regimens, with similar baseline characteristics. At week 24, BIC/FTC/TAF was associated with a higher proportion of VS (75.6% vs 56.5%; adjusted odds ratio [aOR], 2.78 [95% confidence interval {CI}, 1.28-6.25]) and with a lower proportion of IR (47.7% vs 61.9%; aOR, 0.49 [95% CI, .25-.99]). These differences disappeared by week 48. The proportion of treatment discontinuations was significantly lower with BIC/FTC/TAF than with other regimens (week 24: 4.4% vs 20.2%; week 48: 10% vs 36.2%). At week 48, the main reasons for discontinuations were adverse events (3.3% vs 8.5%), toxicity prevention (1.1% vs 8.5%), ART simplification (0% vs 10.6%), and treatment failure (2.2% vs 4.3%). CONCLUSIONS: In light of our results, BIC/FTC/TAF is an effective and well-tolerated option for starting ART in people with AIDS.
引用
- Pérez-Valero I, Corona Mata D, Camacho Espejo A, et al. Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study. Clin Infect Dis. 2025. PMID: 40152537. doi:10.1093/cid/ciaf162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。